Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

Wednesday, September 3, 2014

The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas. …read the whole press release here

Tackling hookworm head-on

Monday, September 1, 2014

As some of the world’s most urgent health threats, diseases such as polio, Ebola and influenza have of late received much publicity. Nevertheless, recent studies reveal that anaemia is also emerging as a worrying health disparity, especially among women and children living in poverty. Although perhaps not as dramatic as the infections mentioned above, anaemia has been shown to have devastating and long-term effects on childhood cognition and intellect, and to increase the risk of maternal morbidity and mortality.

Remko van Leeuwen, Martin Grobusch and Peter Hotez briefly explain why the HOOKVAC programme is now needed more than ever in the article [pdf] Tackling hookworm head-on published in ‘[pdf] Progress through Partnership: The UvA and Africa‘.


EU Flag
This project has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement no 602843.
Copyright © HOOKVAC 2014. All rights reserved.